Evaxion Historical Financial Ratios
| EVAX Stock | USD 1.14 0.05 4.20% |
Evaxion Biotech is recently reporting on over 91 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 4.3 K or Invested Capital of 0.0 will help investors to properly organize and evaluate Evaxion Biotech AS financial condition quickly.
Evaxion |
About Evaxion Financial Ratios Analysis
Evaxion Biotech ASFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Evaxion Biotech investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Evaxion financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Evaxion Biotech history.
Evaxion Biotech Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Evaxion Biotech AS stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Evaxion Biotech sales, a figure that is much harder to manipulate than other Evaxion Biotech AS multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Net Debt To E B I T D A
A leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA).Quick Ratio
A measure of a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as (current assets - inventories) divided by current liabilities.Most ratios from Evaxion Biotech's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Evaxion Biotech AS current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evaxion Biotech AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At this time, Evaxion Biotech's Days Payables Outstanding is fairly stable compared to the past year. ROE is likely to rise to 4.91 in 2024, whereas PTB Ratio is likely to drop (4.16) in 2024.
| 2023 | 2024 (projected) | Graham Number | 17.75 | 33.51 | Receivables Turnover | 0.0611 | 0.0543 |
Evaxion Biotech fundamentals Correlations
Click cells to compare fundamentals
Evaxion Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Evaxion Biotech fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 17.11 | 22.76 | (1.71) | (0.58) | (3.97) | (4.16) | |
| Book Value Per Share | 5.78 | 4.34 | 16.64 | (30.74) | (1.73) | (1.82) | |
| Free Cash Flow Yield | (0.0442) | (0.0801) | (0.27) | (0.62) | (0.95) | (0.9) | |
| Operating Cash Flow Per Share | (4.34) | (7.68) | (11.25) | (10.9) | (6.47) | (6.8) | |
| Capex To Depreciation | 0.75 | 3.74 | 3.95 | 0.51 | 0.14 | 0.13 | |
| Pb Ratio | 17.11 | 22.76 | (1.71) | (0.58) | (3.97) | (4.16) | |
| Free Cash Flow Per Share | (4.38) | (7.92) | (11.95) | (11.03) | (6.5) | (6.83) | |
| Roic | (1.08) | (2.13) | 0.52 | 0.35 | (5.47) | (5.19) | |
| Inventory Turnover | (13.5K) | (0.0153) | (0.18) | (0.23) | (0.21) | (0.22) | |
| Net Income Per Share | (6.91) | (9.27) | (12.58) | (9.8) | (8.09) | (8.5) | |
| Days Of Inventory On Hand | (0.027) | (23.9K) | (2.0K) | (1.6K) | (1.4K) | (1.5K) | |
| Payables Turnover | 0.13 | 0.0288 | 0.12 | 0.27 | 4.2E-5 | 4.0E-5 | |
| Cash Per Share | 5.9 | 3.6 | 16.5 | 5.58 | 2.04 | 1.94 | |
| Pocfratio | (22.8) | (12.88) | (3.93) | (1.63) | (1.06) | (1.11) | |
| Interest Coverage | (8.89) | (74.3) | (28.23) | (16.75) | (24.75) | (25.98) | |
| Capex To Operating Cash Flow | (0.008682) | (0.0316) | (0.062) | (0.0113) | (0.004918) | (0.005164) | |
| Pfcf Ratio | (22.61) | (12.49) | (3.7) | (1.61) | (1.05) | (1.11) | |
| Days Payables Outstanding | 2.9K | 12.7K | 3.0K | 1.3K | 8.8M | 9.2M | |
| Income Quality | 0.63 | 0.83 | 0.89 | 1.11 | 0.8 | 0.62 | |
| Roe | (1.2) | (2.13) | 0.49 | 0.32 | 4.68 | 4.91 | |
| Ev To Operating Cash Flow | (21.45) | (12.41) | (2.63) | (1.2) | (1.36) | (1.43) | |
| Pe Ratio | (14.31) | (10.67) | (3.51) | (1.81) | (0.85) | (0.89) | |
| Return On Tangible Assets | (1.01) | (1.27) | (0.61) | 0.39 | (1.72) | (1.8) | |
| Ev To Free Cash Flow | (21.26) | (12.03) | (2.48) | (1.19) | (1.35) | (1.42) | |
| Earnings Yield | (0.0699) | (0.0937) | (0.28) | (0.55) | (1.18) | (1.12) | |
| Net Debt To E B I T D A | 0.8 | 0.35 | 1.18 | 0.48 | (0.25) | (0.23) | |
| Current Ratio | 0.89 | 6.36 | 1.18 | 8.03 | 3.71 | 1.12 | |
| Tangible Book Value Per Share | 5.78 | 4.28 | 16.59 | (30.74) | (1.73) | (1.82) | |
| Graham Number | 29.98 | 30.11 | 85.59 | 82.33 | 17.75 | 33.51 | |
| Shareholders Equity Per Share | 5.78 | 4.34 | (25.87) | (30.74) | (1.73) | (1.82) | |
| Capex Per Share | 0.0377 | 0.24 | 0.7 | 0.12 | 0.0318 | 0.0302 | |
| Graham Net Net | 5.27 | (1.57) | 12.05 | (0.76) | (4.11) | (3.9) | |
| Interest Debt Per Share | 0.75 | 0.15 | 1.07 | 1.52 | 3.49 | 2.17 | |
| Enterprise Value Over E B I T D A | (12.66) | (9.38) | (2.39) | (1.37) | (1.12) | (1.18) | |
| Price Earnings Ratio | (14.31) | (10.67) | (3.51) | (1.81) | (0.85) | (0.89) | |
| Price Book Value Ratio | 17.11 | 22.76 | (1.71) | (0.58) | (3.97) | (4.16) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Evaxion Stock Analysis
When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.